Shares of DexCom(DXCM) - Get Report have bounced back 15% since hitting a 52-week low early last month, yet the stock is still down 20% so far in 2016. Kevin Sayer, CEO of Dexcom, said top-line growth expectations of 20% and advances in its mobile glucose monitoring app will maintain the momentum for the rest of the year.

DexCom supplies continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by health care providers in hospitals for the treatment of patients with and without diabetes.

"Less than 20% of people with Type 1 diabetes use continuous glucose monitoring, so there is a lot of room in our core market to go and a lot of patients to add," said Sayer. "On top of that, glucose monitoring is also applicable to people who have Type 2 diabetes and are intensive insulin users. So there is a lot of room for growth in the U.S."

Total revenue at DexCom grew to $402 million in 2015, an increase of 55% from the $259.2 million in total revenue for the comparable period in 2014. DexCom lost $57.6 million, or 72 cents per share, last year. That compares to a loss of $22.4 million, or 30 cents, per share, for the same period in 2014. In fiscal 2016, the company set its revenue range from $540 to $560 million, a growth of 20%.

Outside its core domestic market, DexCom also sold $16 million of its products internationally in its fourth quarter. Sayer said he expects that to grow in coming months.

"We've received some very good reimbursement in Sweden and other countries on the verge," said Sayer. The company is focusing on breakthroughs in the U.K. and Germany, he added.

Right now, DexCom is pushing its G5 mobile app, Sayer said. The company is currently negotiating with the FDA over its next-generation G6 app. It will be offering more information to investors in coming weeks, he said.

On the topic of insurance reimbursement, Sayer said users tend to pay cash because the process remains slow. He said DexCom wants to sell at the pharmacy level to reduce the lag.

"We are investing commercially in our strategic channel team this year to move more of our business to that channel," said Sayer. "That will make it easier for our patients and easier on our company and on our system."